Atopic dermatitisReview of comorbidities and therapeuticsAtopic dermatitis (AD) is a very common skin disease associated with substantial burdens on patient health and quality of life. Knowledge regarding the pathogenesis of AD has expanded within recent years, leading to novel and efficacious therapeutic agents. Similarly, our knowledge of the impact of AD on patient's mental and physical health has also expanded. This review summarizes updates on the evolution, comorbidities, and therapeutic options of AD. AD is associated with increased cardiovascular risk, allergic diseases, and adverse mental health outcomes.
T2-low: what do we know?: Past, present, and future of biologic therapies in noneosinophilic asthmaT2-low asthma is an often severe asthma subtype with limited treatment options and biologic therapeutics are lacking. Several monoclonal antibodies (mAbs) targeting non-T2 cytokines were previously reported to be ineffective in asthma. These trials often investigated heterogeneous asthma populations and negative outcomes could be related to unsuitable study cohorts. More tailored approaches in selecting participants based on specific biomarkers have been beneficial in treating severe T2-high asthma.
Allergic and eosinophilic asthma in the era of biomarkers and biologics: similarities, differences and misconceptionsSevere asthma is associated with substantial personal and economic burden; maintaining disease control is the key management goal. Increased understanding of asthma heterogeneity and development of type 2 (T2)-targeting biologics has substantially advanced disease management and outcomes; however, despite both being driven by T2 inflammation, allergic and eosinophilic asthma have different treatment recommendations. We sought to better understand the similarities and differences between allergic and eosinophilic asthma and highlight where misconceptions may arise.
Evaluating enrollment and outcome criteria in trials of biologics for chronic rhinosinusitis with nasal polypsTreatment for chronic rhinosinusitis with nasal polyps (CRSwNP) generally involves intranasal corticosteroids (INCS) and saline irrigation, followed by short courses of systemic corticosteroids (SCS) or surgery with postoperative medical therapy for patients who do not respond to INCS. However, both SCS use and surgery are associated with a range of adverse effects or complications, have a high recurrence rate, and are unsuitable for some patients. Biologics targeting the underlying pathophysiology are promising treatment alternatives for these patients.
2013 Wilderness & Environmental Medicine Peer ReviewersThe editors wish to express their sincere appreciation to the following individuals who faithfully and skillfully performed peer reviews for articles submitted to Wilderness & Environmental Medicine. WEM continues to have a growing impact on the scientific community. We want to acknowledge the importance of our peer reviewers to the process of ensuring the merit and quality of the manuscripts that we publish. Many of these peer reviewers reviewed multiple papers, some also serve on the Editorial Board and have Section Editor duties as well.